Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

20 Jul 2020

Abstract excerpt

OBJECTIVE: To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4μg/mL from a multi-national surveillance study. METHODS: The MIC measurement in the presence of β-lactamase inhibitors and whole genome sequencing were performed. RESULTS: The MIC decrease of CFDC by β-lactamase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Nosocomial Infections in ICU

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32702396
DOI: 10.1016/j.jgar.2020.07.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)PMID 32702396Read ↗

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant MechanismsSemantic proximity Read ↗

High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in ChinaSemantic proximity Read ↗

Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing <em>Enterobacteriaceae</em>: Insights from Comparative GenomicsSemantic proximity Read ↗

In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.Semantic proximity Read ↗

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance MechanismsSemantic proximity Read ↗

Mechanism of action of cefiderocolSemantic proximity Read ↗

Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infectionSemantic proximity Read ↗

In vitro activity of cefiderocol against carbapenemase-producing and meropenem-nonsusceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance (JARBS-GNR)Semantic proximity Read ↗

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical TrialsSemantic proximity Read ↗

Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolatesSemantic proximity Read ↗

Environmental reservoir of resistance genes for the last resort antibiotic CefiderocolSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance ProgramSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.